Management of diabesity:Current concepts  

作　　者：Maria Michaelidou Joseph M Pappachan Mohammad Sadiq Jeeyavudeen 

机构地区：[1]Department of Endocrinology and Metabolism,Lancashire Teaching Hospitals NHS Trust,Preston PR29HT,United Kingdom [2]Faculty of Science,Manchester Metropolitan University,Manchester M156BH,United Kingdom [3]Faculty of Biology,Medicine and Health,The University of Manchester,Manchester M139PL,United Kingdom [4]Department of Endocrinology&Metabolism,University Hospitals of Edinburgh,Edinburgh EH164SA,United Kingdom

出　　处：《World Journal of Diabetes》2023年第4期396-411,共16页世界糖尿病杂志（英文版）（电子版）

摘　　要：The global prevalence of obesity is increasing rapidly with an exponential rise in incidence of type 2 diabetes mellitus in recent years.‘Diabesity’,the term coined to show the strong interlink between obesity and diabetes,is the direct cons-equence of the obesity pandemic,and poses significant challenges in the management of the disease.Without addressing the clinical and mechanistic complications of obesity such as metabolic-associated fatty liver disease and obstructive sleep apnoea,a rational management algorithm for diabesity cannot be developed.Several classes of anti-diabetic medications including insulins,sulphonylureas,thiazolidinediones and meglitinides are associated with the risk of weight gain and may potentially worsen diabesity.Therefore,appropriate selection of antidiabetic drug regimen is crucial in the medical management of diabesity.The role of non-pharmacological measures such as dietary adjustments,exercise interventions and bariatric procedures should also be emphasised.Unfortunately,the importance of appropriate and optimal management of diabesity is often overlooked by medical professionals when achieving adequate glycemic control which results in inappropriate management of the disease and its complications.This review provides a narrative clinical update on the evidence behind the management of diabesity.

关 键 词：OBESITY DIABESITY Metabolic-associated fatty liver disease Antidiabetic medications Glycemic control Metabolic surgery 

分 类 号：R587.1[医药卫生—内分泌]